(MedPage Today) — First-line treatment of advanced acral melanoma with the PD-1 inhibitor toripalimab (Loqtorzi) resulted in a small but statistically significant increase in progression-free survival (PFS) compared with treatment with dacarbazine…
Source link : https://www.medpagetoday.com/hematologyoncology/skincancer/119251
Author :
Publish date : 2026-01-02 19:17:00
Copyright for syndicated content belongs to the linked Source.
